Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kobayashi Profit Increases Due to Success in Generic Drug Business

This article was originally published in PharmAsia News

Executive Summary

For the third fiscal quarter, Kobayashi Pharmaceutical's profits increased by 2.6 percent even as its revenue decreased by 11 percent. President Yutaka Kobayashi credits the increase to its mergers and acquisitions strategies in its generic drug business. Kobayashi's generic, metabolic syndrome drug Naishitoru, launched in 2006, has brought in ¥3.5 billion ($32.7 million) in annual revenue. In 2005, Kobayashi bought the brand Inochi no Haha, a generic menopause drug with ¥0.3 billion ($2.8 million) in estimated annual revenue. In the first year following the purchase, Inochi no Haha surpassed the ¥1 billion in revenue. Already a major player in the generic drug industry, Kobayshi sees more space to grow in this area, and its M&A will not only focus on large companies, but also on mid-sized firms. (Click for more-Japanese language

You may also be interested in...



FDA To Periodically Publish List Of NOAs Due To COVID-19, But No Impact On EUA Sponsors

Due to strained resources and the slew of emergency use authorizations being requested by sponsors because of the COVID-19 crisis, the agency will now periodically publish Notices of Availabilities in the Federal Register instead of publishing immediately as the EUAs are handed out. However, companies will still get their NOA letters and can start marketing their products, and the agency will post the announcements sooner on its website.

Bigfoot Biomedical Closes $55M Series C Financing, Plans FDA Filing For Diabetes System

Diabetes-care company Bigfoot Biomedical announced it raised $55m in a Series C round to support US FDA submission for its insulin delivery system.

Warning Letter Close-Outs – May 2020

The US FDA released three device-related close-out letters in May.

UsernamePublicRestriction

Register

LL1132553

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel